Skip to menu Skip to content Skip to footer

2006

Conference Publication

Prolonged hematologic toxicity from the Hyper-CVAD regimen; manifestations, frequency, and natural history in a cohort of 125 consecutive patients

Gill, Saar, Lane, Steven, Crawford, Julie, Mollee, Peter, Marlton, Paula, Cull, Gavin, Prince, Miles and Seymour, John Francis (2006). Prolonged hematologic toxicity from the Hyper-CVAD regimen; manifestations, frequency, and natural history in a cohort of 125 consecutive patients. 48th Annual Meeting of the American-Society-of-Hematology, Orlando, FL, United States, 9-12 December 2006. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood.v108.11.2441.2441

Prolonged hematologic toxicity from the Hyper-CVAD regimen; manifestations, frequency, and natural history in a cohort of 125 consecutive patients

2006

Journal Article

Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF)supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy

Lane, Steven W., Crawford, Julie, Kenealy, Melita, Cull, Gavin, Seymour, John F., Prince, H. Miles, Marlton, Paula, Gill, Devinder ‌ and Mollee, Peter‌ N. (2006). Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF)supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy. Leukemia and Lymphoma, 47 (9), 1813-1817. doi: 10.1080/10428190600632832

Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF)supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy

2006

Conference Publication

Characterisation and prognostic significance of WT-1 gene expression in acute myeloid leukemia (AML).

Lane, SW, Saal, R, Negus, S, Mollee, P, Mather, M, Gill, D, Mills, AK, Bird, RJ, Hourigan, MJ, Jones, M and Marlton, P (2006). Characterisation and prognostic significance of WT-1 gene expression in acute myeloid leukemia (AML).. 48th Annual Meeting of the American-Society-of-Hematology, Orlando Fl, Dec 09-12, 2006. WASHINGTON: AMER SOC HEMATOLOGY.

Characterisation and prognostic significance of WT-1 gene expression in acute myeloid leukemia (AML).

2006

Journal Article

Hereditary fibrinogen A alpha-chain amyloidosis

Lane, S. W., Goodman, H. J., Francis, L., Bofinger, A. M. and Mollee, P. N. (2006). Hereditary fibrinogen A alpha-chain amyloidosis. Pathology, 38 (4), 380-382. doi: 10.1080/00313020600820823

Hereditary fibrinogen A alpha-chain amyloidosis

2006

Conference Publication

Real-time quantitative polymerase chain reaction (RQ-PCR) monitoring of minimal residual disease (MRD) in core binding factor acute myeloid leukaemia (CBF AML).

Lane, SW, Saal, R, Mollee, P, Grigg, A, Taylor, K, Seymour, JF, Kennedy, G, Williams, B, Jones, M, Grimmett, K, Griffiths, V, Gill, D, Hourigan, M and Marlton, P (2006). Real-time quantitative polymerase chain reaction (RQ-PCR) monitoring of minimal residual disease (MRD) in core binding factor acute myeloid leukaemia (CBF AML).. 48th Annual Meeting of the American-Society-of-Hematology, Orlando, FL, United States, 9-12 December 2006. Washington, DC, United States: American Society of Hematology.

Real-time quantitative polymerase chain reaction (RQ-PCR) monitoring of minimal residual disease (MRD) in core binding factor acute myeloid leukaemia (CBF AML).

2005

Journal Article

Role of VAD in the initial treatment of multiple myeloma

Lane, Steven W., Gill, Devinder, Mollee, Peter N. and Rajkumar, S. Vincent (2005). Role of VAD in the initial treatment of multiple myeloma. Blood, 106 (10), 3674-3675. doi: 10.1182/blood-2005-07-2610

Role of VAD in the initial treatment of multiple myeloma

2005

Journal Article

Intestinal Pseudo-Obstruction Complicating Multiple Sclerosis

Lane, S. W. and Pender, M. P. (2005). Intestinal Pseudo-Obstruction Complicating Multiple Sclerosis. Internal Medicine Journal, 35 (3), 191-192. doi: 10.1111/j.1445-5994.2004.00753.x

Intestinal Pseudo-Obstruction Complicating Multiple Sclerosis

2005

Conference Publication

Pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) with hyper-CVAD chemotherapy regimen for aggressive lymphoid malignancy.

Lane, SW, Crawford, J, Kenealy, M, Cull, G, Seymour, JF, Prince, M, Marlton, P, Gill, D and Mollee, PN (2005). Pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) with hyper-CVAD chemotherapy regimen for aggressive lymphoid malignancy.. 47th Annual Meeting of the American-Society-of-Hematology, Atlanta, GA, United States, 10-13 December 2005. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood.V106.11.4274.4274

Pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) with hyper-CVAD chemotherapy regimen for aggressive lymphoid malignancy.

2005

Conference Publication

Aggressive cutaneous squamous cell carcinoma (SCC) in chronic lymphocytic leukaemia (CLL)

Lane, S. W., Mollee, P. N., Bird, R., Porceddu, S. and Gill, D. (2005). Aggressive cutaneous squamous cell carcinoma (SCC) in chronic lymphocytic leukaemia (CLL). 47th Annual Meeting of the American Society of Hematology, Atlanta, GA, United States, 10-13 December 2005. Washington, DC, United States: American Society of Hematology.

Aggressive cutaneous squamous cell carcinoma (SCC) in chronic lymphocytic leukaemia (CLL)

1977

Conference Publication

Orthodontic Surgery, An Adjunct to Cleft-Palate Treatment

Lane, SW, Hoffman, S and Gibbs, SL (1977). Orthodontic Surgery, An Adjunct to Cleft-Palate Treatment.

Orthodontic Surgery, An Adjunct to Cleft-Palate Treatment